Abstract:The kinesin spindle protein (KSP), a member of the kinesin superfamily of microtubule-based motors, plays a critical role in mitosis as it mediates centrosome separation and bipolar spindle assembly and maintenance. Inhibition of KSP function leads to cell cycle arrest at mitosis with the formation of monoastral microtubule arrays, and ultimately, to cell death. Several KSP inhibitors are currently being studied in clinical trials and provide new opportunities for the development of novel anticancer therapeutics. RNA interference (RNAi) may represent a powerful strategy to interfere with key molecular pathways involved in cancer. In this study, we have established an efficient method for intratumoral delivery of siRNA. We evaluated short interfering RNA (siRNA) duplexes targeting luciferase as surrogate marker or KSP sequence. To examine the potential feasibility of RNAi therapy, the siRNA was transfected into pre-established lesions by means of intratumor electro-transfer of RNA therapeutics (IERT). This technology allowed cell permeation of the nucleic acids and to efficiently knock down gene expression, albeit transiently. The KSP-specific siRNA drastically reduced outgrowth of subcutaneous melanoma and ovarian cancer lesions. Our results show that intratumoral electro-transfer of siRNA is feasible and KSP-specific siRNA may provide a novel strategy for therapeutic intervention.

Progress of Kinesin Spindle Protein Inhibitors

Progress on Kinesin Spindle Protein Inhibitors As Anti-Cancer Agents

Kinesin Spindle Protein Inhibitors As Anticancer Agents

Kinesin Spindle Protein (KSP) Inhibitors in Combination with Chemotherapeutic Agents for Cancer Therapy

Kinesin Spindle Protein Inhibitors in Cancer: a Patent Review (2008 – Present)

Progress in ATP-competitive Kinesin Spindle Protein Inhibitors as Anticancer Agents

Kinesin Spindle Protein Inhibition in Translational Research

De Novo Design, Synthesis and Biological Evaluation of 1,4-Dihydroquinolin-4-ones and 1,2,3,4-Tetrahydroquinazolin-4-ones As Potent Kinesin Spindle Protein (KSP) Inhibitors

Kinesin spindle protein (KSP) inhibitors. Part 2: The design, synthesis, and characterization of 2,4-diaryl-2,5-dihydropyrrole inhibitors of the mitotic kinesin KSP

Kinesin Spindle Protein (KSP) Inhibitors. Part 6: Design and Synthesis of 3,5-Diaryl-4,5-dihydropyrazole Amides As Potent Inhibitors of the Mitotic Kinesin KSP.

Design, synthesis and biological evaluation of novel KSP inhibitors

Synthesis, Biological Evaluation and Molecular Docking Studies of Flavone and Isoflavone Derivatives As a Novel Class of KSP (kinesin Spindle Protein) Inhibitors

[Synthesis and Antitumor Activity of Novel Tetrahydro-Beta-carboline Derivatives As KSP Inhibitors].

Kinesin Spindle Protein (KSP) Inhibitors. 9. Discovery of (2<i>S</i>)-4-(2,5-Difluorophenyl)-<i>N</i>-[(3<i>R</i>,4<i>S</i>)-3-fluoro-1-methylpiperidin-4-yl]-2-(hydroxymethyl)-<i>N</i>-methyl-2-phenyl-2,5-dihydro-1<i>H</i>-pyrrole-1-carboxamide (MK-0731) for the Treatment of Taxane-Refractory Cancer

Synthesis and biological evaluation of tetrahydro-β-carline derivatives

Oncogenic role of kinesin proteins and targeting kinesin therapy.

Discovery of tetrahydro-beta-carbolines as inhibitors of the mitotic kinesin KSP.

Oncogenic Role of Kinesin Proteins and Targeting Kinesin Therapy

Discovery of Novel KSP-targeting PROTACs with Potent Antitumor Effects in Vitro and in Vivo

Exploration of inhibitors targeting KIF18A with ploidy-specific lethality

Kinesin spindle protein SiRNA slows tumor progression